Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs
Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs
复制标题
DOI：
10.1016/j.seizure.2020.09.026
复制
发表时间：
2020-12-01
影响因子：
3
通讯作者：
Casadevall, Teresa
中科院分区：
文献类型：
--
作者：
Santamarina, Estevo;Bertol, Vicente;Casadevall, Teresa
目的：研究perampanel（PER）作为局灶性癫痫或特发性全身性癫痫（IGE）患者的首个添加治疗给药的疗效和耐受性，这些患者正在服用另一种抗癫痫药物（ASD）。方法：这项多中心、回顾性、为期1年的观察性研究收集了开始使用PER作为首个添加治疗的患者（≥ 12岁）的数据。患者在ASD单药治疗时癫痫控制不佳，
Purpose: To investigate the efficacy and tolerability of perampanel (PER) when administered as a first add-on therapy to patients with focal epilepsy or idiopathic generalized epilepsy (IGE) taking one other antiseizure drug (ASD).Methods: This multicentre, retrospective, one-year observational study collected data from patients (>= 12 years) who initiated treatment with PER as first add-on therapy. Patients had to be experiencing inadequate seizure control on ASD monotherapy and tried